DOASENSE - Home - Pioneering Point-of-Care Testing for DOACs

Go to content
Pioneering Novel Approaches to Testing for DOACs
 NEWS FLASH:
      • 2024-02: Expert consensus published on algorithm for rapid exclusion of clinically relevant plasma levels of DOACs using the DOAC Dipstick  [download here]

      • 2024-01: Updated version of White Paper available with a summary of key publications on the DOASENSE test suite [download here]

      • 2023-11: DOASENSE becoming a standard of care in Italy and Estonia [read more]

      • 2023-09: DOASENSE announces new partnership with PHILCARE as appointed exclusive distributor for the Philippines [contact details]

      • 2023-05: New partnership with Eurobio Scientific -- appointed exclusive distributor of DOASENSE solutions in France [read more / contact details]

      • 2023-02: New study published in STROKE, provides evidence for using the DOAC Dipstick test to identify patients for prompt thrombolysis [read more]

      • 2022-02: DOAC Dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in plasma [download open access paper]

    READ ALL NEWS [HERE]
    When every minute counts … fast DOAC testing matters.

    DOASENSE’s mission objective is changing the landscape of testing for DOACs (new synthetic oral anticoagulants) with novel and quick point-of-care urine tests

    The determination of DOACs has long been limited to blood sampling approaches, with all their potential limitations, and a rapid assessment of the anticoagulant effect of non-vitamin K antagonist oral anticoagulants (Direct Oral AntiCoagulants – DOACs) by point-of-care testing (POCT) so far has been an unmet clinical need.


    DOASENSE offers products for specific testing for DOACs in urine

    Tests which are easy to use and easy to interpret, reproducible, and patient friendly

    Listen to what opinion leaders think about DOASENSE's solutions:
    Typical clinical scenarios where testing for specific DOACs can be of value

      • Stroke (e.g. before thrombolytic therapy)
      • Trauma
      • Emergency procedures
      • Evaluating for venous thromboembolism
      • Spontaneous hemorrhage
      • General surgery or invasive procedures
      • Other situations where medication history may not available

    In each of these situations the objective is establishing the absence of DOACs in the patient prior to procedure

    Accelerate your clinical decisions and treat patients earlier!


    Please note that our products are for health care professional use only!
    Divider
    NOTE: DOASENSE(TM) products may not be available or approved in your country.


    Copyright (c) 2016-2024 DOASENSE GmbH. All rights reserved.
    Back to content